Global Atopic Dermatitis Market Overview
Atopic dermatitis (AD) is a type of skin disorder in which the skin becomes dry, itchy and inflamed. Scratching of the skin leads to, swelling, scaling, cracking, weeping, redness and crusting. Though this condition is most common in children, also affects the adult population. Generally, people with AD develop hay fever.
The Global Atopic Dermatitis Market was worth USD XX billion in 2017 and is forecasted to reach USD XX billion by 2025, growing at a CAGR of XX% during the forecast period (2018-2025).
Global Atopic Dermatitis Market– Market Dynamics
An increasing number of pipeline products for atopic dermatitis is one of the major driving factor leading to the growth of the market. The pipeline of more targeted topical and systemic therapies is expanding based on growing demand for unmet treatment of AD. The pipeline for atopic dermatitis is impressive with the majority of drugs in stage III and II. Once launched upon the successful completion of the development cycle, these drugs will boost the market growth significantly.
On the other side, The treatment of Atopic dermatitis consists of emollient therapy, and daily skin hydration, but the majority of patients still require symptomatic treatment with corticosteroids and calcineurin inhibitors, which are associated with potential long-term side effects. Some side effects of topical treatment include- atrophy (the skin becomes thin), lichenification (the skin becomes thick, stretch marks and skin darkening.
Global Atopic Dermatitis Market– Segment Analysis
Based on the distribution channel the market is segmented into Hospitals, Dermatology Clinics, Retail Pharmacy, and Online Pharmacy. Of these, the hospital segment is the largest segment in 2017. Further, The pharmacy department in hospital under the direction of a qualified pharmacist is responsible for the procurement, storage, and distribution of medication throughout the hospital. The sale of atopic dermatitis drugs in hospitals is relatively low compared with retail channels. However, in emerging markets, pharma companies promote their drugs through physicians and hospitals due to lack of awareness among end-users about the prescription.
Global Atopic Dermatitis Market– Geographical Analysis
Geographically, the Global Atopic Dermatitis Market is segmented into Asia-Pacific, North America, Europe, South America, and RoW. Of these, North America is expected to account for the largest market share for the atopic dermatitis market owing to several factors such as high treatment awareness among the patient population across US and Canada, early adoption of novel medications, and healthcare infrastructure. Healthcare organizations with Established Clinical guidelines, improved care and appropriate standards for dermatological diseases is supporting the growth of Atopic Dermatitis market in the North American region.
Europe holds the second largest market share, owing to the government support for research & development and availability. This is expected to drive the European market over the forecasted period. For instance, countries like France and Germany are increasing investment in the healthcare domain.
Global Atopic Dermatitis Market– Competitive Analysis
The Global Atopic Dermatitis Market products are fragmented with a large number of local and international players. However, Some of the most important manufacturersand suppliers of the atopic dermatitis market are LEO Pharma, Mylan, Novartis, Pfizer, Inc, Sanofi, and Valeant. These companies are mostly focused on the capacity of expansion due to increasing demand for atopic dermatitis in various industries. For instance, in February 2018, Sanofi has launched Dupixent™ in Canada for treating moderate-to-severe atopic dermatitis (AD) in adults.
Global Atopic Dermatitis Market Segmentation:
- By Disease Severity
- By Treatment Type
- Calcineurin Inhibitors
- Biologic Therapy
- PDE-4 Inhibitor
- Off-Label Therapies
- By Distribution Channel
- Dermatology Clinics
- Retail Pharmacy
- Online Pharmacy
- Company Profiles
- LEO Pharma
- Pfizer, Inc
- By Region
- North America
- Asia Pacific